ATOM · Atomera Incorporated

Atomera's first quarter 2026 results reflect the company's continued investment in research and development and sales efforts as it pursues licensing of its MST technology. Revenue remained nominal at $11,000, consistent with the early-stage licensing model. The net loss of $6.1 million widened from $5.2 million in the same quarter last year, primarily due to higher operating expenses: R&D increased to $3.5 million (from $3.3 million), G&A rose to $2.3 million (from $2.1 million), and selling and marketing expenses grew to $0.4 million (from $0.1 million). Stock-based compensation of $1.4 million contributed to the expense growth. Adjusted EBITDA loss was $4.9 million versus $4.4 million a year ago. The balance sheet strengthened significantly with cash, equivalents and short-term investments of $41.1 million as of March 31, 2026, up from $19.2 million at year-end 2025, following a $25 million registered direct offering of common stock. Management highlighted progress in engaging with GAA manufacturers and expanding GaN offerings into RF applications, which could broaden the total addressable market. No forward guidance was provided.